U.S. Interactive Media and Services Stock News

NYSE:WY
NYSE:WYSpecialized REITs

Weyerhaeuser (WY) Could Be 3% Undervalued As Valuation Questions Follow 2025 Results

Weyerhaeuser (WY) is drawing investor attention after reporting 2025 net sales of US$6.9b and net income of US$397m, prompting closer scrutiny of how the timber and wood products business is currently valued. See our latest analysis for Weyerhaeuser. Recent trading has been positive, with Weyerhaeuser's share price delivering a 1 day return of 3.52%, a 30 day share price return of 6.93% and a 90 day share price return of 7.20%. Over the same period, the 3 year total shareholder return...
NYSE:KR
NYSE:KRConsumer Retailing

Does Kroger (KR) Prioritizing Dividends and Rewards Clarify Its Long‑Term Capital Allocation Strategy?

Kroger recently approved its 20th consecutive annual dividend increase, lifting the payout to US$1.56 per year, with the next quarterly dividend of US$0.39 per share scheduled for September 1, 2026, for shareholders of record on August 15, 2026. This higher dividend, alongside refreshed loyalty benefits that let members redeem Points for groceries or fuel, underlines management’s emphasis on both shareholder returns and everyday customer value amid ongoing cost and execution pressures. We’ll...
NYSE:ELV
NYSE:ELVHealthcare

The Bull Case For Elevance Health (ELV) Could Change Following Health OS, CNSide Coverage Expansion - Learn Why

CNSide Diagnostics announced a national agreement with Elevance Health, effective May 1, 2026, extending access to its CNSide cerebrospinal fluid tumor cell enumeration assay to about 45.4 million people and lifting total contracted coverage to 126 million lives across the US. Together with Elevance Health’s Health OS data platform, which has already processed over 250,000 electronic prior authorizations in 2026, these moves highlight the company’s push to tie advanced diagnostics and...
NasdaqGS:RGEN
NasdaqGS:RGENLife Sciences

Moderated 2026 Guidance and Sector Weakness Might Change The Case For Investing In Repligen (RGEN)

In Q1 2026, institutional investors reported that Repligen’s updated 2026 guidance, including moderated revenue and organic growth expectations, weighed on fund performance as market sentiment toward life-sciences tools weakened. An interesting wrinkle is that some investors highlighted Repligen’s lack of exposure to pressured National Institutes of Health funding and management’s earlier bullish tone, underscoring how broader sector mood can influence sentiment even when company-specific...
NasdaqGS:ROAD
NasdaqGS:ROADConstruction

How Investors Are Reacting To Construction Partners (ROAD) Refinancing Its Term Loan B And Adding Debt

On June 18, 2026, Construction Partners, Inc. amended its Term Loan B Credit Agreement, refinancing existing term loans, adding US$300.0 million of incremental term loans maturing November 1, 2031, and slightly lowering interest margins subject to leverage conditions. The amendment also introduces modestly more flexible covenants and the ability to exclude certain “Immaterial Subsidiaries” from guarantees, potentially giving the company greater financial and operational flexibility as it...
NasdaqGS:ZM
NasdaqGS:ZMSoftware

Is Zoom’s Workflow-Embedded AI Strategy Quietly Reshaping the Investment Narrative for Zoom (ZM)?

Recently, Canary Speech Inc. made its Canary Ambient voice analytics tool available in the Zoom App Marketplace, enabling clinicians using Zoom telehealth visits to access real-time behavioral and cognitive health insights during patient sessions. On top of this, Zoom introduced new AI capabilities for its Virtual Agent, including the Agent Architect and Agent Performance Suite, aiming to simplify the creation and monitoring of AI-powered customer-service agents across voice and chat...
NasdaqGS:WGS
NasdaqGS:WGSHealthcare

GeneDx Holdings (WGS) Names Mark Gardner President, Is It Still Below Fair Value?

Why Mark Gardner’s Appointment Matters For GeneDx Holdings Stock GeneDx Holdings (WGS) has drawn fresh attention after appointing Mark Gardner as President, a leadership change focused on commercial execution and operational scale that could influence how investors view the company’s long-term direction. See our latest analysis for GeneDx Holdings. The appointment of Mark Gardner comes as GeneDx Holdings trades at US$63.54, with a 1 day share price return of 9.4% and a 30 day share price...
NYSE:ORC
NYSE:ORCMortgage REITs

The Bull Case For Orchid Island Capital (ORC) Could Change Following Expanded Buyback And Updated Book Value Estimate

Orchid Island Capital, Inc. recently expanded its stock repurchase authorization to up to 26,612,580 shares, representing about 13.3% of its outstanding common stock, with no set termination date and flexibility across open market and privately negotiated transactions. Alongside the enlarged buyback capacity, the company estimated its book value per share at roughly US$7.24 to US$7.28 as of June 18, 2026, highlighting balance sheet metrics that are central to how investors may assess the...
NYSE:VICI
NYSE:VICISpecialized REITs

Can VICI Properties (VICI) Justify A 22% Undervaluation View?

Recent Performance Context for VICI Properties Stock VICI Properties (VICI) has seen its stock move in different directions across timeframes, with a modest gain over the past day alongside declines over the past week, month, and past 3 months. For longer term holders, VICI Properties shows a mixed picture, with the stock down over the past year while still recording a positive total return over the past 3 years and past 5 years. See our latest analysis for VICI Properties. At a share price...
NYSE:SUI
NYSE:SUIResidential REITs

REIT Stocks In Focus As Fed Pause Puts Rate Sensitive Property Plays Back On Radar

Interest rate sensitive Real Estate Investment Trusts, or REITs, sit right in the crosshairs of the Federal Reserve’s recent signal that it may pause rate hikes, especially as inflation data shows signs of cooling. Stable borrowing costs can affect property values, refinancing decisions, and investor appetite for income focused stocks. This article looks at three REIT stocks from our screener that appear especially exposed to the latest Fed and inflation headlines. It outlines how each stock...
NasdaqGS:VIAV
NasdaqGS:VIAVCommunications

Ultra Ethernet AI Fabric Test Launch Could Be A Game Changer For Viavi Solutions (VIAV)

Earlier this month, Viavi Solutions launched what it calls the industry's first Ultra Ethernet Transport validation solution for AI fabrics, a GPU-free platform that emulates full-fidelity AI traffic to help hyperscalers, cloud providers and equipment makers test next-generation high-speed networks more efficiently. This move underscores Viavi’s effort to become a core testing partner for emerging AI data center architectures, as Ultra Ethernet gains traction for large-scale AI...
NasdaqGM:FRPT
NasdaqGM:FRPTFood

Freshpet Leadership Transition and New President Role Might Change The Case For Investing In Freshpet (FRPT)

Freshpet, Inc. has announced that co-founder and President Scott Morris will retire from his operating role on October 20, 2026, shifting to an 18‑month advisory position while Chief Operating Officer Nicola (Nicki) Baty becomes President and COO. This transition, along with broader leadership changes including expanded HR and administrative responsibilities, marks a significant evolution of Freshpet’s management structure as it enters its third decade. We’ll explore how Nicki Baty’s...
NasdaqGM:BLZE
NasdaqGM:BLZEIT

Backblaze (BLZE) On CoreWeave Deal Has A Pricey AI Growth Narrative

Backblaze (BLZE) is back in focus after signing a multi exabyte cloud storage agreement with AI infrastructure provider CoreWeave, a five year deal valued at about US$335 million. See our latest analysis for Backblaze. The CoreWeave agreement has arrived at a time when momentum in Backblaze has already been strong, with a 30 day share price return of 56.06% and a 90 day share price return of 241.03% feeding into a 1 year total shareholder return of 123.74%. If this AI storage contract has you...
NYSE:CHD
NYSE:CHDHousehold Products

How Slower Organic Growth And Flat Sales Forecasts At Church & Dwight (CHD) Have Changed Its Investment Story

In recent days, coverage of Church & Dwight highlighted that the Arm & Hammer owner has delivered slower organic revenue growth than many consumer staples peers, with analysts now projecting largely flat sales over the coming year. This combination of muted demand expectations and an already optimistic valuation has raised questions about how the company can justify its growth ambitions without clearer drivers. Now, we'll examine how concerns over stagnant near-term revenue expectations...
NYSE:PLD
NYSE:PLDIndustrial REITs

Prologis (PLD) Pushes SEGRO Shareholders After £12.6 Billion Bid Rebuff

Prologis has proposed a £12.6b all stock takeover of UK warehouse group SEGRO. SEGRO's board unanimously rejected the offer, calling it undervalued and opportunistically timed. Prologis is now publicly urging SEGRO shareholders to pressure the board to re engage on the proposal. The situation has drawn attention to potential shifts in the European logistics real estate sector. For investors tracking Prologis (NYSE:PLD), this move comes with the stock around $140.87 and multi year returns...
NasdaqGS:CVBF
NasdaqGS:CVBFBanks

CVB Financial (CVBF) Gains Momentum, Is The Stock Already Fully Valued?

Without a specific news headline driving attention, CVB Financial (CVBF) is drawing interest as investors weigh its recent share performance and core banking metrics against the broader regional banking sector. See our latest analysis for CVB Financial. CVB Financial’s recent share price return of 2.32% over 1 day, 7.19% over 7 days and 8.35% over 30 days contributes to an 18.10% year to date share price return and a 19.52% 1 year total shareholder return. This suggests that momentum has been...
NasdaqGS:RVMD
NasdaqGS:RVMDBiotechs

How Launching a Pivotal RAS G12D Pancreatic Cancer Trial At Revolution Medicines (RVMD) Has Changed Its Investment Story

Revolution Medicines has already begun treating patients in RASolute 305, a global, randomized Phase 3 trial testing zoldonrasib plus standard chemotherapy versus placebo plus chemotherapy as first-line treatment for metastatic RAS G12D pancreatic ductal adenocarcinoma, with primary endpoints of progression-free survival and overall survival. This marks one of the first late-stage attempts to directly target the prevalent RAS G12D mutation, for which no approved targeted therapies currently...
NYSE:PLNT
NYSE:PLNTHospitality

Can Planet Fitness’ New Dual-Role CFO Redefine PLNT’s Global Growth and Capital Allocation Strategy?

Planet Fitness recently appointed Sudhanshu Priyadarshi as Chief Financial Officer and President, International, placing him in charge of finance, investor relations, strategy, IT, and the company’s global expansion efforts, with former interim CFO Tom Fitzgerald supporting the transition through mid-September 2026. By combining the CFO and international president roles in an executive with extensive experience across more than 80 countries, Planet Fitness is explicitly tying its financial...
NYSE:VLO
NYSE:VLOOil and Gas

Valero Energy (VLO) Stock After 83% Year Gain Is There Still Upside Potential

If you are wondering whether Valero Energy stock still offers value after a strong run, this article walks through what the current price could mean for you. With the share price at US$242.43 and returns of 1.1% over 7 days, a decline of 1.8% over 30 days, 46.7% year to date and 83.2% over 1 year, many investors are asking whether the recent performance already reflects the key positives or changes in risk. Recent headlines around Valero Energy have focused on broader energy sector trends...
NYSE:ECL
NYSE:ECLChemicals

Ecolab (ECL) Stock After Recent Run Looks Pricey Versus Cash Flow And Earnings Models

If you are wondering whether Ecolab stock is offering genuine value at current levels, this breakdown will walk through what the numbers are saying and how that lines up with expectations. Ecolab recently closed at US$276.29, with returns of 2.7% over the past week, 9.1% over the past month, 5.2% year to date, 4.8% over 1 year, 57.4% over 3 years and 41.8% over 5 years. These figures give useful context before comparing the current price to different valuation estimates. Recent coverage...
NYSE:DMC
NYSE:DMCFood

Del Monte (FDP) Marks Pineapple Day As DMC Ticker Change Nears

Del Monte (NYSE:FDP) is marking International Pineapple Day by spotlighting its pineapple portfolio, including Pinkglow®, Honeyglow®, and Rubyglow® varieties. The company is using the celebration to emphasize its role in making pineapple an everyday staple across global markets. Del Monte plans to change its stock symbol to DMC, signaling an updated approach to global brand stewardship. The ticker change is described as imminent, aligning with the company’s broader push into new markets and...
NYSE:FDX
NYSE:FDXLogistics

FedEx (FDX) Stock Faces Margin Stagnation As Earnings Growth Narrative Gets Tested

FedEx (FDX) has wrapped up FY 2026 with fourth quarter revenue of US$25.0 billion, basic EPS of US$6.63 and quarterly net income of US$1,598 million, setting the tone for how investors will read the latest numbers against the broader story. Over the last two reported fourth quarters, revenue has gone from US$22.2 billion to US$25.0 billion, while basic EPS has shifted from US$6.92 to US$6.63, giving you a clear view of how the top and bottom lines are tracking into the current year. With one...
NYSE:KTB
NYSE:KTBLuxury

Kontoor Brands’ Zacks Downgrade and CAO Transition Might Change The Case For Investing In KTB

Kontoor Brands recently announced that long-serving Vice President and Chief Accounting Officer S. Denise Sumner will retire in August 2026, with Andrew Taylor, the current Controller of Accounting and Reporting, set to assume the CAO role at that time while Sumner remains as an adviser through early 2027. Around the same time, Kontoor Brands was placed on the Zacks Rank #5 (Strong Sell) list after a very large downward revision to the consensus earnings estimate, underscoring fresh concern...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly (LLY) Stock After 410% Five Year Run Is There Still Value?

If you are wondering whether Eli Lilly stock still offers fair value after its strong run, this article walks through what the current price might imply about future expectations. At a last close of US$1,117.26, Eli Lilly has returned 0.5% over the past week, 4.9% over the past month, 3.4% year to date and 42.0% over the past year, with a very large 3 year gain of 148.8% and 5 year gain of 410.3% helping to shape sentiment around the stock. Recent coverage around Eli Lilly has focused on its...